{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T04:45:14Z","timestamp":1790484314241,"version":"4.1.0"},"reference-count":49,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2008,11,10]],"date-time":"2008-11-10T00:00:00Z","timestamp":1226275200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Basic Clin Pharma Tox"],"published-print":{"date-parts":[[2009,1]]},"abstract":"<jats:p><jats:bold>Abstract:\u2002<\/jats:bold> Aromatase inhibitors increase the disease\u2010free survival in patients with receptor\u2010positive breast cancer. Aromatase is a cytochrome P450 enzyme complex catalysing the conversion of androgens to oestrogens. These properties cause a significant increase in bone loss. In this <jats:italic>MiniReview<\/jats:italic>, we present data from the aromatase inhibitor studies and the studies designed to investigate aromatase inhibitor effect on bone metabolism. At the cellular level, oestrogen has profound effects on both osteoblasts and osteoclasts. Oestrogen decreases the osteoblastic production of resorptive cytokines and simultaneously increases the production of antireceptive cytokines, which leads to increased osteoclastic apoptosis and increased osteoblastic activity. Aromatase inhibitors inhibit the endogenous production of oestrogen by 50\u201390%. Studies designed to look at the effect of aromatase inhibitors on bone mineral density have shown a significant decrease in bone mineral density of the femoral neck in the aromatase inhibitor groups compared to placebo groups. Placebo\u2010controlled studies lack statistical power to detect changes in fracture incidence; however, aromatase inhibitors increase the incidence of fractures in comparison with tamoxifen. We conclude that treatment with aromatase inhibitors leads to an increased bone loss and thus an increase in the risk of fractures in women with breast cancer.<\/jats:p>","DOI":"10.1111\/j.1742-7843.2008.00337.x","type":"journal-article","created":{"date-parts":[[2008,11,10]],"date-time":"2008-11-10T19:08:56Z","timestamp":1226344136000},"page":"3-10","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["The Effect of Aromatase Inhibitors on Bone Metabolism"],"prefix":"10.1111","volume":"104","author":[{"given":"Lars","family":"Folkestad","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nina H.","family":"Bjarnason","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jon Kroll","family":"Bjerregaard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kim","family":"Brixen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2008,12,17]]},"reference":[{"key":"e_1_2_12_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0305-7372(02)00036-1"},{"key":"e_1_2_12_3_2","first-page":"1","article-title":"Danish breast cancer cooperative group informationsblad Nr. 37","volume":"37","author":"Christiansen P.","year":"2005","journal-title":"DBCG Informationsblad"},{"key":"e_1_2_12_4_2","doi-asserted-by":"publisher","DOI":"10.1093\/ajhp\/62.3.266"},{"key":"e_1_2_12_5_2","doi-asserted-by":"publisher","DOI":"10.1210\/er.2004-0015"},{"key":"e_1_2_12_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(04)17666-6"},{"key":"e_1_2_12_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(05)67059-6"},{"key":"e_1_2_12_8_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa052258"},{"key":"e_1_2_12_9_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa032312"},{"key":"e_1_2_12_10_2","first-page":"3072","article-title":"Medicinsk efterbehandling af brystkr\u00e6ft","volume":"169","author":"Mouridsen HT","year":"2007","journal-title":"Ugeskr L\u00e6g"},{"key":"e_1_2_12_11_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2796.1996.429781000.x"},{"key":"e_1_2_12_12_2","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/90.18.1371"},{"key":"e_1_2_12_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsbmb.2005.04.002"},{"key":"e_1_2_12_14_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.10908"},{"key":"e_1_2_12_15_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa040331"},{"key":"e_1_2_12_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0960-0760(01)00126-1"},{"key":"e_1_2_12_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsbmb.2005.04.009"},{"key":"e_1_2_12_18_2","doi-asserted-by":"publisher","DOI":"10.1210\/jc.83.7.2239"},{"key":"e_1_2_12_19_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11914-003-0009-4"},{"key":"e_1_2_12_20_2","first-page":"15","article-title":"Androgens and the skeleton","volume":"30","author":"Lindberg MK","year":"2005","journal-title":"Minerva Endocrinol"},{"key":"e_1_2_12_21_2","first-page":"109","article-title":"Osteoblast cells (MG\u201063 and HOS) have aromatase and 5 alpha\u2010reductase activities","volume":"39","author":"Shimodaria K","year":"1996","journal-title":"Biochem Mol Biol Int"},{"key":"e_1_2_12_22_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.bone.2006.11.029"},{"key":"e_1_2_12_23_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.bone.2003.11.006"},{"key":"e_1_2_12_24_2","doi-asserted-by":"publisher","DOI":"10.1359\/jbmr.1999.14.7.1217"},{"key":"e_1_2_12_25_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-04-0438"},{"key":"e_1_2_12_26_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-04-0261"},{"key":"e_1_2_12_27_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.07.097"},{"key":"e_1_2_12_28_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(07)70003-7"},{"key":"e_1_2_12_29_2","first-page":"S35","article-title":"Intergroup exemestane study: 1\u2010year results of the bone sub\u2010protocol","volume":"87","author":"Coleman R","year":"2005","journal-title":"Breast Cancer Res Treat"},{"key":"e_1_2_12_30_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.bone.2006.06.027"},{"key":"e_1_2_12_31_2","doi-asserted-by":"publisher","DOI":"10.1359\/jbmr.2002.17.1.172"},{"key":"e_1_2_12_32_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.05.4882"},{"key":"e_1_2_12_33_2","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdi322"},{"issue":"5","key":"e_1_2_12_34_2","first-page":"32","article-title":"Results of the \u2018Arimidex\u2019 (anastrozole, A), tamoxifen (T), alone or in combination (C) (ATAC) trial: effects on bone mineral density (BMD) and bone turnover (ATAC Trialists\u2019 Group)","volume":"13","author":"Eastell R","year":"2002","journal-title":"Ann Oncol"},{"key":"e_1_2_12_35_2","doi-asserted-by":"publisher","DOI":"10.1007\/s001980170006"},{"key":"e_1_2_12_36_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(02)09088-8"},{"key":"e_1_2_12_37_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00223-008-9132-7"},{"key":"e_1_2_12_38_2","doi-asserted-by":"publisher","DOI":"10.1359\/JBMR.0301240"},{"key":"e_1_2_12_39_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6690188"},{"key":"e_1_2_12_40_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(02)08657-9"},{"key":"e_1_2_12_41_2","doi-asserted-by":"publisher","DOI":"10.1080\/13697130500118027"},{"key":"e_1_2_12_42_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.295.23.joc60074"},{"key":"e_1_2_12_43_2","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2004-1444"},{"key":"e_1_2_12_44_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1999.17.3.846"},{"key":"e_1_2_12_45_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1447-0756.2007.00634.x"},{"key":"e_1_2_12_46_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1359-6349(07)70769-3"},{"key":"e_1_2_12_47_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(97)11423-4"},{"key":"e_1_2_12_48_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6602688"},{"key":"e_1_2_12_49_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.03.903"},{"key":"e_1_2_12_50_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199203263261302"}],"container-title":["Basic &amp; Clinical Pharmacology &amp; Toxicology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1742-7843.2008.00337.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1742-7843.2008.00337.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,11]],"date-time":"2023-10-11T00:54:46Z","timestamp":1696985686000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1742-7843.2008.00337.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,12,17]]},"references-count":49,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2009,1]]}},"alternative-id":["10.1111\/j.1742-7843.2008.00337.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1742-7843.2008.00337.x","archive":["Portico"],"relation":{},"ISSN":["1742-7835","1742-7843"],"issn-type":[{"value":"1742-7835","type":"print"},{"value":"1742-7843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,12,17]]},"assertion":[{"value":"2008-12-17","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}